Quarterly report pursuant to Section 13 or 15(d)

Acquisition of Patents and Intangibles - Additional Information (Detail)

v3.20.4
Acquisition of Patents and Intangibles - Additional Information (Detail) - USD ($)
3 Months Ended 6 Months Ended
Oct. 16, 2012
Nov. 30, 2020
Nov. 30, 2019
Nov. 30, 2020
Nov. 30, 2019
May 31, 2020
Acquired Finite-Lived Intangible Assets [Line Items]            
Intangible asset acquired gross   $ 3,500,000   $ 3,500,000   $ 3,500,000
Issuance of common stock shares   590,279,000   590,279,000   519,261,000
Common stock per shares   $ 0.001   $ 0.001   $ 0.001
ProstaGene, LLC            
Acquired Finite-Lived Intangible Assets [Line Items]            
Acquisition of ProstaGene LLC, value       $ 11,558,000    
Issuance of common stock shares   20,278,000   20,278,000    
Common stock per shares   $ 0.57   $ 0.57    
ProstaGene, LLC | Dr .Pestell | Stock Restriction Agreement            
Acquired Finite-Lived Intangible Assets [Line Items]            
Restricted common stock, shares   8,342,000   8,342,000    
Common stock shares restriction period       3 years    
Stock repurchase price, per share       $ 0.001    
ProstaGene, LLC | Investment Advisory, Management and Administrative Service            
Acquired Finite-Lived Intangible Assets [Line Items]            
Investment earned shares   1,620,000   1,620,000    
Patents            
Acquired Finite-Lived Intangible Assets [Line Items]            
Asset purchase, cash paid $ 3,500,000          
Estimated useful life of acquired asset   10 years        
Amortization expense related to acquired patents   $ 500,000 $ 500,000 $ 1,000,000.0 $ 1,000,000.0